JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: Tafenoquine (formerly known as WR-238605; Brand name of Krintafel) is an 8-aminoquinoline analog and oral drug developed by GlaxoSmithKline that has been investigated as a potential treatment for malaria, as well as for malaria prevention. Tafenoquine targets leishmania respiratory complex III and induces apoptosis. Tafenoquine has a long half-life of approximately 14 days and is generally safe and well tolerated. In July 2018, United States Food and Drug Administration (US FDA) approved single dose tafenoquine for the radical cure (prevention of relapse) of Plasmodium vivax malaria.
References: J Travel Med. 2018 Jan 1; 25(1). doi: 10.1093/jtm/tay110; J Travel Med. 2018 Dec 11. doi: 10.1093/jtm/tay133.
Related CAS#:106635-81-8( succinate)
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Recommend by mail
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!